

Substitute form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/817,023
		Filing Date	April 2, 2004
		First Named Inventor	Pizzo et al.
		Group Art Unit	1632 / 648
		Examiner Name	Unknown Emily C
Sheet A	Of	Attorney Docket Number	5405-304

U.S. PATENTS AND PATENT PUBLICATIONS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
ele	1	US- 6,270,758		Staats et al.	08-07-2001
ele	2	US- 6,413,935		Sette et al.	07-02-2002
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			


FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
ele	3	LENNEY et al. "Antimicrobial Action of Compound 48/80 against Protozoa, Bacteria and Fungi." <u>Journal of Pharmaceutical Sciences</u> , 1997. Vol. 66, No. 5, pages 702-705.	
	4	MALAVIYA et al. "Mast Cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha." <u>Nature</u> , 1996. Vol 381, pages 77-80.	
	5	PCT International Search Report for International Application No. PCT/US04/10429, Mailed August 12, 2005 (2 pages)	
	6	SIGMA. Compound 48/80, Sigma product number C2313, December 15, 1997, Saint Louis. (2 pages)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/817,023
		Filing Date	April 2, 2004
		First Named Inventor	PIZZO
		Group Art Unit	1648
		Examiner Name	Emily M. Le
Sheet	1B of 1B	Attorney Docket Number	5405-305



U.S. PATENT APPLICATIONS				
Examiner Initials*	Cite No.	U.S. Serial No.	Name of Applicant of Cited Document	Date of Filing of Cited Document MM-DD-YYYY
elle	1.	US- 2005/0063978	FRITZ et al.	03-24-2005
		US-		
		US-		
		US-		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			
elle	2.	PCT	WO02/32451		CISTEM BIOTECHNOLOGIES GMBH	04-25-2002	

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
elle	3.	FRITZ et al. (2004) "The Artificial Antimicrobial Peptide KLKLLLLLKLK Induces Predominantly a T _H 2-type immune response to co-injected antigens." Vaccine 22, pp. 3274-3284.	

Examiner Signature	<i>Emily M. Le</i>	Date Considered	5/31/07
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.